Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not
hand-edited; a correction means re-running the fetch against a newer release.
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
01–1011–100101–1,0001,001–10,000over 10,000not in the reporting set
Cases of Japanese encephalitis reported to WHO by national authorities, latest year 2025. Reported cases undercount true infections, and a zero can mean elimination or simply that nobody reported — each country page carries a data-quality grade saying which. This is occurrence as reported, not a modelled distribution.
What it does
29
disease-burden figures
11
post-infectious sequelae figures
32
effectiveness estimates
2
vaccine adverse-event figures
7
randomised trial
6
pooled or expert review
14
controlled observational
5
surveillance, ecological, modelling
Deaths per year 2019
20,642 estimated annual global JE deaths (n)
all ages, JE-endemic countries globally per population
quote
Based on the baseline number of people at risk of infection, there were an estimated 56,847 (95% CI: 18,003-184,525) JE cases and 20,642 (95% CI: 2,252-77,204) deaths in 2019.
Moore SM 2021 PLoS Negl Trop Dis
Case-fatality 2000-2018
14 CFR (%)
all ages, age-stratified data pooled, JE-endemic countries, multiple per case
quote
Results suggested overall JE CFR estimates of 26% (95% CI 22, 30) in 1961-1979, 20% (95% CI 17, 24) in 1980-1999, 14% (95% CI 11, 17) in 2000-2018, and 14% (95% CI 11, 17) in 2019-2030.
Cheng Y 2022 PLoS Negl Trop Dis
Cases per year 2019
56,847 estimated annual global JE cases (n)
all ages, JE-endemic countries globally per population
quote
Based on the baseline number of people at risk of infection, there were an estimated 56,847 (95% CI: 18,003-184,525) JE cases and 20,642 (95% CI: 2,252-77,204) deaths in 2019.
Moore SM 2021 PLoS Negl Trop Dis
Lowest and highest vaccine effectiveness reported:43.8%(Tandale BV 2018 J Infect Public Health; Laboratory-confirmed Japanese encephalitis (IgM ELISA or RT-PCR) among hospitalised AES cases, children aged 1-15 years) to 99.3%(Bista MB 2001 Lancet; Hospitalised Japanese encephalitis with serological evidence of recent infection, children aged 1-15 years). Two of 9 estimates, each from its own study; not a summary figure.
Controlled observational
Vaccine effectiveness against hospitalisation or severe disease 6
What can follow the illness
Full recovery at hospital discharge after JE
36 proportion of JE patients recovered fully at discharge (%)
all ages, JE-endemic countries, multiple
quote
For disability, we estimated that 36% (min-max 0-85) JE patients recovered fully at hospital discharge.
Cheng Y 2022 PLoS Negl Trop Dis
Neurological sequelae one year after discharge in JE survivors
49 proportion of survivors with neurological sequelae at 1 year (%)
all ages, JE-endemic countries, multiple
quote
One year after hospital discharge, 46% (min-max 0%-97%) JE survivors were estimated to live normally but 49% (min-max 3% - 86%)till had neurological sequelae.
Cheng Y 2022 PLoS Negl Trop Dis
Severe sequelae (likely dependent) after childhood JE
25 proportion with severe sequelae (%)
children, Indonesia
quote
Sixteen children (25%) had severe sequelae, indicating their function was impaired enough to likely make them dependent.
Maha MS 2009 Int J Infect Dis
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
After the infection: post-infectious syndromes 2After vaccination: adverse events 8
Clinical description: when it is observed to begin
Product label observation window
Study risk window: when events were counted, not typical onset
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are
on the label and in national guidelines. This page does not give medical advice and does not
render dosing. A development stage is not a measure of how well something works.
Cite this page. Japanese encephalitis virus. Vaccine Data Navigator, Open Source Medicine Foundation. Built 9 November 2026 from the ICTV Virus Metadata Resource (MSL41) and NCBI Taxonomy/GenBank. https://vaccinedatanavigator.org/virus-navigator/viruses/japanese-encephalitis-virus.html